Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 5, 2011, Pages 920-926

  Kozak, Margaret M ^a   Murphy, James D ^a   Schipper, Meike L ^b   Donington, Jessica S ^c   Zhou, Lisa ^a   Whyte, Richard I ^a   Shrager, Joseph B ^a   Hoang, Chuong D ^a   Bazan, Jose ^a   Maxim, Peter G ^a   Graves, Edward E ^a   Diehn, Maximilian ^a   Hara, Wendy Y ^a   Quon, Andrew ^b   Le, Quynh Thu ^a   Wakelee Jr , Heather A ^b   Loo, Billy W ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Automatic deformable image registration; Lung cancer; Positron emission tomography computed tomography (PET CT); Trimodality therapy; Volumetric response assessment

Indexed keywords

CARBOPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; GROWTH FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79955421128     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31821517db     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010.
3. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced nonsmall- cell lung cancer. J Clin Oncol 2010;28:2181-2190.
4. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-450. (Pubitemid 47073567)
5. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-386.
6. Piper J. Evaluation of an intensity-based free-form deformable registration algorithm [Abstract SU-FF-I-68]. Med Phys 2007;34:2353-2354.
7. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-481.
8. Das M, Donington JS, Murphy JD, et al. Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer. Clin Lung Cancer In press.
9. Kupelian PA, Ramsey C, Meeks SL, et al. Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys 2005;63:1024-1028. (Pubitemid 41505279)
10. Siker ML, Tomé WA, Mehta MP. Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect? Int J Radiat Oncol Biol Phys 2006;66:135-141. (Pubitemid 44175657)
11. Bosmans G, van Baardwijk A, Dekker A, et al. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2006;66:748-753. (Pubitemid 44436690)
12. Woodford C, Yartsev S, Dar AR, et al. Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int J Radiat Oncol Biol Phys 2007;69:1316-1322. (Pubitemid 47625877)
13. Britton KR, Starkschall G, Tucker SL, et al. Assessment of gross tumor volume regression and motion changes during radiotherapy for nonsmall- cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 2007;68:1036-1046. (Pubitemid 47048566)
14. Fox J, Ford E, Redmond K, et al. Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;74:341-348.
15. Guckenberger M, Baier K, Richter A, et al. Evolution of surface-based deformable image registration for adaptive radiotherapy of non-small cell lung cancer (NSCLC). Radiat Oncol 2009;4:68.
16. Bral S, Duchateau M, De Ridder M, et al. Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC. Radiother Oncol 2009; 91:438-442.
17. Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002;52:49-57. (Pubitemid 34041565)
18. Etiz D, Marks LB, Zhou S-M, et al. Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;53:835-846. (Pubitemid 34722627)
19. Willner J, Baier K, Caragiani E, et al. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:382-389. (Pubitemid 34173001)
20. Basaki K, Abe Y, Aoki M, et al. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 2006;64:449-454. (Pubitemid 43083431)
21. Werner-Wasik M, Swann RS, Bradley J, et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2008;70:385-390.
22. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-smallcell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1039-1044. (Pubitemid 351308062)
23. van Baardwijk A, Wanders S, Boersma L, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010;28:1380-1386.
24. Alexander BM, Othus M, Caglar HB, et al. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys In press.
25. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007;69:328-333. (Pubitemid 47380105)
26. Loo BW, Lee P, Bazan JG, et al. Metabolic tumor volume predicts disease progression and overall survival in lung cancer [Abstract P1- 082]. J Thorac Oncol 2007;2:S582.
27. Olson MR, Weerasuriya DK, Wakelee HA, et al. Mid-treatment FDGPET predicts disease progression in patients with non-small cell lung cancer [Abstract 2542]. Int J Radiat Oncol Biol Phys 2007;69:S504.
28. Chang C, Olson M, Weerasuriya D, et al. Mid-radiation FDG-PET is a prognostic factor for disease progression in patients with non-small cell lung cancer. Proceedings of the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, 2008.
29. Kong F, Haken RKT, Gross M, et al. FDG-PET/CT during radiation therapy to predict survival and guide individualized adaptive dose escalation in patients with non-small-cell lung cancer [Abstract 74]. Int J Radiat Oncol Biol Phys 2009;75:S35-S36.
30. de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 2010;5:389-398.
31. Tsuji SY, Hwang A, Weinberg V, et al. Dosimetric evaluation of automatic segmentation for adaptive IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010;77:707-714.